B
Boston Scientific Corporation
BSX
$98.66
$0.490.50%
B
Buy
6/24/2024Downgrade
Boston Scientific Corporation (BSX) was downgraded to B- from B on 6/24/2024 due to a decline in the growth index, valuation index and efficiency index. Operating cash flow declined 82.86% from $957M to $164M, earnings per share declined from $0.3391 to $0.33, and net income declined 1.98% from $504M to $494M.
Boston Scientific Corporation (BSX) was downgraded to B- from B on 6/24/2024 due to a decline in the growth index, valuation index and efficiency index. Operating cash flow declined 82.86% from $957M to $164M, earnings per share declined from $0.3391 to $0.33, and net income declined 1.98% from $504M to $494M.
B
Buy
2/21/2024Upgraded
Boston Scientific Corporation (BSX) was upgraded to B from B- on 2/21/2024 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 37.11% from $698M to $957M, total revenue increased 5.61% from $3.53B to $3.73B, and EBIT increased 1.31% from $609M to $617M.
Boston Scientific Corporation (BSX) was upgraded to B from B- on 2/21/2024 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 37.11% from $698M to $957M, total revenue increased 5.61% from $3.53B to $3.73B, and EBIT increased 1.31% from $609M to $617M.
B
Buy
1/22/2024Upgraded
Boston Scientific Corporation (BSX) was upgraded to B- from C+ on 1/22/2024 due to a major increase in the total return index, volatility index and solvency index.
Boston Scientific Corporation (BSX) was upgraded to B- from C+ on 1/22/2024 due to a major increase in the total return index, volatility index and solvency index.
C
Hold
11/3/2023Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 11/3/2023 due to a noticeable increase in the valuation index, growth index and efficiency index. Earnings per share increased from $0.18 to $0.34, net income increased 86.67% from $270M to $504M, and operating cash flow increased 6.08% from $658M to $698M.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 11/3/2023 due to a noticeable increase in the valuation index, growth index and efficiency index. Earnings per share increased from $0.18 to $0.34, net income increased 86.67% from $270M to $504M, and operating cash flow increased 6.08% from $658M to $698M.
C
Hold
6/21/2023Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 6/21/2023 due to a decline in the total return index, volatility index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 6/21/2023 due to a decline in the total return index, volatility index and valuation index.
C
Hold
6/2/2023Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 6/2/2023 due to a significant increase in the growth index, total return index and volatility index. Earnings per share increased from $0.0879 to $0.2089, EBIT increased 10.84% from $526M to $583M, and total revenue increased 4.53% from $3.24B to $3.39B.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 6/2/2023 due to a significant increase in the growth index, total return index and volatility index. Earnings per share increased from $0.0879 to $0.2089, EBIT increased 10.84% from $526M to $583M, and total revenue increased 4.53% from $3.24B to $3.39B.
C
Hold
12/13/2022Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 12/13/2022 due to an increase in the total return index, volatility index and solvency index.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 12/13/2022 due to an increase in the total return index, volatility index and solvency index.
C
Hold
11/4/2022Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 11/4/2022 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.17 to $0.12, total revenue declined 2.28% from $3.24B to $3.17B, and EBIT declined 2.12% from $518M to $507M.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 11/4/2022 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.17 to $0.12, total revenue declined 2.28% from $3.24B to $3.17B, and EBIT declined 2.12% from $518M to $507M.
C
Hold
5/5/2022Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 5/5/2022 due to a decline in the volatility index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 5/5/2022 due to a decline in the volatility index.
C
Hold
2/28/2022Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 2/28/2022 due to an increase in the growth index and volatility index. EBIT increased 44.98% from $458M to $664M, total revenue increased 6.65% from $2.93B to $3.13B, and operating cash flow increased 2.8% from $465M to $478M.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 2/28/2022 due to an increase in the growth index and volatility index. EBIT increased 44.98% from $458M to $664M, total revenue increased 6.65% from $2.93B to $3.13B, and operating cash flow increased 2.8% from $465M to $478M.
C
Hold
1/10/2022Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 1/10/2022 due to a decline in the total return index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 1/10/2022 due to a decline in the total return index and valuation index.
C
Hold
11/16/2021Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 11/16/2021 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.12 to $0.28, net income increased 125.27% from $186M to $419M, and total capital increased 2.02% from $25.41B to $25.92B.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 11/16/2021 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.12 to $0.28, net income increased 125.27% from $186M to $419M, and total capital increased 2.02% from $25.41B to $25.92B.
C
Hold
5/10/2021Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 5/10/2021 due to a large increase in the total return index, growth index and solvency index. Earnings per share increased from $0.1371 to $0.23, the quick ratio increased from 0.89 to 1.07, and debt to equity declined from 0.6 to 0.58.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 5/10/2021 due to a large increase in the total return index, growth index and solvency index. Earnings per share increased from $0.1371 to $0.23, the quick ratio increased from 0.89 to 1.07, and debt to equity declined from 0.6 to 0.58.
C
Hold
2/25/2021Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C+ on 2/25/2021 due to a significant decline in the valuation index, growth index and efficiency index. Total capital declined 0.86% from $25.16B to $24.94B.
Boston Scientific Corporation (BSX) was downgraded to C- from C+ on 2/25/2021 due to a significant decline in the valuation index, growth index and efficiency index. Total capital declined 0.86% from $25.16B to $24.94B.
C
Hold
11/10/2020Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 11/10/2020 due to a significant increase in the growth index, solvency index and volatility index. EBIT increased 954.55% from -$33M to $282M, operating cash flow increased 139.03% from $269M to $643M, and total revenue increased 32.75% from $2B to $2.66B.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 11/10/2020 due to a significant increase in the growth index, solvency index and volatility index. EBIT increased 954.55% from -$33M to $282M, operating cash flow increased 139.03% from $269M to $643M, and total revenue increased 32.75% from $2B to $2.66B.
C
Hold
8/7/2020Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 8/7/2020 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.0079 to -$0.11, net income declined 1,436.36% from $11M to -$147M, and EBIT declined 113.41% from $246M to -$33M.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 8/7/2020 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.0079 to -$0.11, net income declined 1,436.36% from $11M to -$147M, and EBIT declined 113.41% from $246M to -$33M.
C
Hold
6/30/2020Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 6/30/2020 due to an increase in the volatility index and valuation index.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 6/30/2020 due to an increase in the volatility index and valuation index.
C
Hold
5/26/2020Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 5/26/2020 due to a decline in the volatility index, solvency index and total return index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 5/26/2020 due to a decline in the volatility index, solvency index and total return index.
C
Hold
5/8/2020Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 5/8/2020 due to an increase in the volatility index.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 5/8/2020 due to an increase in the volatility index.
C
Hold
5/6/2020Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 5/6/2020 due to a decline in the volatility index, total return index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 5/6/2020 due to a decline in the volatility index, total return index and valuation index.
C
Hold
4/16/2020Downgrade
Boston Scientific Corporation (BSX) was downgraded to C+ from B- on 4/16/2020 due to a decline in the total return index, volatility index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C+ from B- on 4/16/2020 due to a decline in the total return index, volatility index and valuation index.
B
Buy
3/20/2020Downgrade
Boston Scientific Corporation (BSX) was downgraded to B- from B on 3/20/2020 due to a major decline in the volatility index and total return index.
Boston Scientific Corporation (BSX) was downgraded to B- from B on 3/20/2020 due to a major decline in the volatility index and total return index.
B
Buy
2/13/2020Upgraded
Boston Scientific Corporation (BSX) was upgraded to B from B- on 2/13/2020 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 71.92% from $292M to $502M, and total revenue increased 2.89% from $2.63B to $2.71B.
Boston Scientific Corporation (BSX) was upgraded to B from B- on 2/13/2020 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 71.92% from $292M to $502M, and total revenue increased 2.89% from $2.63B to $2.71B.
B
Buy
11/6/2019Downgrade
Boston Scientific Corporation (BSX) was downgraded to B- from B on 11/6/2019 due to a noticeable decline in the total return index.
Boston Scientific Corporation (BSX) was downgraded to B- from B on 11/6/2019 due to a noticeable decline in the total return index.
B
Buy
8/5/2019Upgraded
Boston Scientific Corporation (BSX) was upgraded to B from B- on 8/5/2019 due to a substantial increase in the growth index, total return index and efficiency index. Total revenue increased 5.54% from $2.49B to $2.63B, total capital increased 2.66% from $18.73B to $19.23B, and EBIT increased 2.05% from $438M to $447M.
Boston Scientific Corporation (BSX) was upgraded to B from B- on 8/5/2019 due to a substantial increase in the growth index, total return index and efficiency index. Total revenue increased 5.54% from $2.49B to $2.63B, total capital increased 2.66% from $18.73B to $19.23B, and EBIT increased 2.05% from $438M to $447M.
B
Buy
6/20/2019Downgrade
Boston Scientific Corporation (BSX) was downgraded to B- from B on 6/20/2019 due to a decline in the valuation index and total return index.
Boston Scientific Corporation (BSX) was downgraded to B- from B on 6/20/2019 due to a decline in the valuation index and total return index.
B
Buy
6/5/2019Upgraded
Boston Scientific Corporation (BSX) was upgraded to B from B- on 6/5/2019 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 1,742.11% from $19M to $350M, and earnings per share increased from $0.2701 to $0.3.
Boston Scientific Corporation (BSX) was upgraded to B from B- on 6/5/2019 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 1,742.11% from $19M to $350M, and earnings per share increased from $0.2701 to $0.3.
B
Buy
4/16/2019Downgrade
Boston Scientific Corporation (BSX) was downgraded to B- from B on 4/16/2019 due to a decline in the total return index.
Boston Scientific Corporation (BSX) was downgraded to B- from B on 4/16/2019 due to a decline in the total return index.
B
Buy
4/1/2019Upgraded
Boston Scientific Corporation (BSX) was upgraded to B from B- on 4/1/2019 due to a noticeable increase in the total return index, valuation index and solvency index.
Boston Scientific Corporation (BSX) was upgraded to B from B- on 4/1/2019 due to a noticeable increase in the total return index, valuation index and solvency index.
B
Buy
2/21/2019Upgraded
Boston Scientific Corporation (BSX) was upgraded to B- from C on 2/21/2019 due to a significant increase in the valuation index, efficiency index and total return index. Total capital increased 6.11% from $14.92B to $15.83B.
Boston Scientific Corporation (BSX) was upgraded to B- from C on 2/21/2019 due to a significant increase in the valuation index, efficiency index and total return index. Total capital increased 6.11% from $14.92B to $15.83B.
C
Hold
2/11/2019Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 2/11/2019 due to a decline in the total return index, volatility index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 2/11/2019 due to a decline in the total return index, volatility index and valuation index.
C
Hold
1/25/2019Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 1/25/2019 due to an increase in the total return index and volatility index.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 1/25/2019 due to an increase in the total return index and volatility index.
C
Hold
1/8/2019Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 1/8/2019 due to a large decline in the total return index and volatility index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 1/8/2019 due to a large decline in the total return index and volatility index.
C
Hold
10/31/2018Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 10/31/2018 due to a major increase in the efficiency index, total return index and volatility index. Total capital increased 4.76% from $14.24B to $14.92B.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 10/31/2018 due to a major increase in the efficiency index, total return index and volatility index. Total capital increased 4.76% from $14.24B to $14.92B.
C
Hold
5/3/2018Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 5/3/2018 due to a significant increase in the growth index, total return index and efficiency index. Net income increased 148.46% from -$615M to $298M, earnings per share increased from -$0.4478 to $0.21, and total capital increased 1.32% from $12.63B to $12.8B.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 5/3/2018 due to a significant increase in the growth index, total return index and efficiency index. Net income increased 148.46% from -$615M to $298M, earnings per share increased from -$0.4478 to $0.21, and total capital increased 1.32% from $12.63B to $12.8B.
C
Hold
4/9/2018Upgraded
Boston Scientific Corporation (BSX) was upgraded to C- from D+ on 4/9/2018 due to an increase in the total return index.
Boston Scientific Corporation (BSX) was upgraded to C- from D+ on 4/9/2018 due to an increase in the total return index.
D
Sell
2/22/2018Downgrade
Boston Scientific Corporation (BSX) was downgraded to D+ from C+ on 2/22/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.2 to -$0.4478, net income declined 317.31% from $283M to -$615M, and total capital declined 4.84% from $13.27B to $12.63B.
Boston Scientific Corporation (BSX) was downgraded to D+ from C+ on 2/22/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.2 to -$0.4478, net income declined 317.31% from $283M to -$615M, and total capital declined 4.84% from $13.27B to $12.63B.
C
Hold
1/2/2018Downgrade
Boston Scientific Corporation (BSX) was downgraded to C+ from B- on 1/2/2018 due to a decline in the volatility index and total return index.
Boston Scientific Corporation (BSX) was downgraded to C+ from B- on 1/2/2018 due to a decline in the volatility index and total return index.
B
Buy
12/18/2017Upgraded
Boston Scientific Corporation (BSX) was upgraded to B- from C+ on 12/18/2017 due to an increase in the valuation index.
Boston Scientific Corporation (BSX) was upgraded to B- from C+ on 12/18/2017 due to an increase in the valuation index.
C
Hold
12/1/2017Downgrade
Boston Scientific Corporation (BSX) was downgraded to C+ from B- on 12/1/2017 due to a major decline in the total return index.
Boston Scientific Corporation (BSX) was downgraded to C+ from B- on 12/1/2017 due to a major decline in the total return index.
B
Buy
11/3/2017Upgraded
Boston Scientific Corporation (BSX) was upgraded to B- from C on 11/3/2017 due to a substantial increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.1066 to $0.2, and operating cash flow increased 37.84% from $185M to $255M.
Boston Scientific Corporation (BSX) was upgraded to B- from C on 11/3/2017 due to a substantial increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.1066 to $0.2, and operating cash flow increased 37.84% from $185M to $255M.
C
Hold
10/5/2017Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 10/5/2017 due to a decline in the valuation index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 10/5/2017 due to a decline in the valuation index.
C
Hold
9/7/2017Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 9/7/2017 due to a large increase in the total return index and volatility index.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 9/7/2017 due to a large increase in the total return index and volatility index.
C
Hold
8/21/2017Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 8/21/2017 due to a large decline in the total return index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 8/21/2017 due to a large decline in the total return index.
C
Hold
8/4/2017Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 8/4/2017 due to a noticeable increase in the valuation index, efficiency index and volatility index. Total capital increased 4% from $12.57B to $13.07B.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 8/4/2017 due to a noticeable increase in the valuation index, efficiency index and volatility index. Total capital increased 4% from $12.57B to $13.07B.
C
Hold
8/2/2017Downgrade
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 8/2/2017 due to a noticeable decline in the total return index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C from C+ on 8/2/2017 due to a noticeable decline in the total return index and valuation index.
C
Hold
5/10/2017Upgraded
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 5/10/2017 due to a substantial increase in the growth index, total return index and efficiency index. Net income increased 133.87% from $124M to $290M, earnings per share increased from $0.09 to $0.21, and total capital increased 2.86% from $12.22B to $12.57B.
Boston Scientific Corporation (BSX) was upgraded to C+ from C on 5/10/2017 due to a substantial increase in the growth index, total return index and efficiency index. Net income increased 133.87% from $124M to $290M, earnings per share increased from $0.09 to $0.21, and total capital increased 2.86% from $12.22B to $12.57B.
C
Hold
3/13/2017Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 3/13/2017 due to a major increase in the total return index and valuation index.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 3/13/2017 due to a major increase in the total return index and valuation index.
C
Hold
2/24/2017Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 2/24/2017 due to a major decline in the growth index and solvency index. Earnings per share declined from $0.1676 to $0.09, and the quick ratio declined from 0.54 to 0.47.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 2/24/2017 due to a major decline in the growth index and solvency index. Earnings per share declined from $0.1676 to $0.09, and the quick ratio declined from 0.54 to 0.47.
C
Hold
2/23/2017Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 2/23/2017 due to an increase in the total return index.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 2/23/2017 due to an increase in the total return index.
C
Hold
12/19/2016Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 12/19/2016 due to a decline in the volatility index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 12/19/2016 due to a decline in the volatility index and valuation index.
C
Hold
12/2/2016Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 12/2/2016 due to an increase in the valuation index and solvency index.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 12/2/2016 due to an increase in the valuation index and solvency index.
C
Hold
11/4/2016Upgraded
Boston Scientific Corporation (BSX) was upgraded to C- from D+ on 11/4/2016 due to a substantial increase in the growth index, efficiency index and solvency index. Net income increased 210.14% from -$207M to $228M, earnings per share increased from -$0.1525 to $0.1676, and EBIT increased 5.83% from $343M to $363M.
Boston Scientific Corporation (BSX) was upgraded to C- from D+ on 11/4/2016 due to a substantial increase in the growth index, efficiency index and solvency index. Net income increased 210.14% from -$207M to $228M, earnings per share increased from -$0.1525 to $0.1676, and EBIT increased 5.83% from $343M to $363M.
D
Sell
10/20/2016Downgrade
Boston Scientific Corporation (BSX) was downgraded to D+ from C- on 10/20/2016 due to a substantial decline in the total return index and volatility index.
Boston Scientific Corporation (BSX) was downgraded to D+ from C- on 10/20/2016 due to a substantial decline in the total return index and volatility index.
C
Hold
10/11/2016Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 10/11/2016 due to a noticeable decline in the total return index and volatility index.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 10/11/2016 due to a noticeable decline in the total return index and volatility index.
C
Hold
9/21/2016Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 9/21/2016 due to a noticeable increase in the total return index and volatility index.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 9/21/2016 due to a noticeable increase in the total return index and volatility index.
C
Hold
9/6/2016Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 9/6/2016 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.1496 to -$0.1525, and the quick ratio declined from 0.62 to 0.57.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 9/6/2016 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.1496 to -$0.1525, and the quick ratio declined from 0.62 to 0.57.
C
Hold
4/28/2016Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 4/28/2016 due to a large increase in the total return index and volatility index.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 4/28/2016 due to a large increase in the total return index and volatility index.
C
Hold
4/13/2016Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 4/13/2016 due to a decline in the total return index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 4/13/2016 due to a decline in the total return index and valuation index.
C
Hold
3/29/2016Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 3/29/2016 due to a noticeable increase in the total return index.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 3/29/2016 due to a noticeable increase in the total return index.
C
Hold
3/14/2016Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 3/14/2016 due to a significant decline in the volatility index, total return index and valuation index.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 3/14/2016 due to a significant decline in the volatility index, total return index and valuation index.
C
Hold
2/26/2016Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 2/26/2016 due to an increase in the growth index, solvency index and volatility index. EBIT increased 1.43% from $279M to $283M, debt to equity declined from 0.91 to 0.9, and total revenue increased 0.64% from $1.89B to $1.9B.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 2/26/2016 due to an increase in the growth index, solvency index and volatility index. EBIT increased 1.43% from $279M to $283M, debt to equity declined from 0.91 to 0.9, and total revenue increased 0.64% from $1.89B to $1.9B.
C
Hold
2/25/2016Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 2/25/2016 due to a decline in the total return index.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 2/25/2016 due to a decline in the total return index.
C
Hold
12/30/2015Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 12/30/2015 due to an increase in the total return index and efficiency index. Total capital increased 4.93% from $11.69B to $12.27B.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 12/30/2015 due to an increase in the total return index and efficiency index. Total capital increased 4.93% from $11.69B to $12.27B.
C
Hold
8/10/2015Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 8/10/2015 due to a noticeable decline in the total return index and volatility index.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 8/10/2015 due to a noticeable decline in the total return index and volatility index.
C
Hold
3/16/2015Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 3/16/2015 due to an increase in the total return index.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 3/16/2015 due to an increase in the total return index.
C
Hold
2/27/2015Downgrade
Boston Scientific Corporation (BSX) was downgraded to C- from C on 2/27/2015 due to a major decline in the growth index, solvency index and efficiency index. Earnings per share declined from $0.03 to -$0.2254, net income declined 795.35% from $43M to -$299M, and the quick ratio declined from 0.82 to 0.62.
Boston Scientific Corporation (BSX) was downgraded to C- from C on 2/27/2015 due to a major decline in the growth index, solvency index and efficiency index. Earnings per share declined from $0.03 to -$0.2254, net income declined 795.35% from $43M to -$299M, and the quick ratio declined from 0.82 to 0.62.
C
Hold
2/28/2014Upgraded
Boston Scientific Corporation (BSX) was upgraded to C from C- on 2/28/2014 due to a large increase in growth and efficiency. Operating cash flow increased 9.2% from $250M to $273M, and total revenue increased 5.94% from $1.74B to $1.84B.
Boston Scientific Corporation (BSX) was upgraded to C from C- on 2/28/2014 due to a large increase in growth and efficiency. Operating cash flow increased 9.2% from $250M to $273M, and total revenue increased 5.94% from $1.74B to $1.84B.
NYSE
01/17/2025 4:00PM Eastern
Quotes delayed
